GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » Sloan Ratio %

OPKO Health (OPKO Health) Sloan Ratio %

: -7.08% (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

OPKO Health's Sloan Ratio for the quarter that ended in Dec. 2023 was -7.08%.

As of Dec. 2023, OPKO Health has a Sloan Ratio of -7.08%, indicating the company is in the safe zone and there is no funny business with accruals.


OPKO Health Sloan Ratio % Historical Data

The historical data trend for OPKO Health's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.59 0.38 -4.35 -14.96 -7.08

OPKO Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.96 -12.97 -4.47 -7.85 -7.08

Competitive Comparison

For the Diagnostics & Research subindustry, OPKO Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health Sloan Ratio % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where OPKO Health's Sloan Ratio % falls into.



OPKO Health Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

OPKO Health's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-188.863--28.197
--18.198)/2011.698
=-7.08%

OPKO Health's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-188.863--28.197
--18.198)/2011.698
=-7.08%

OPKO Health's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -18.267 (Mar. 2023 ) + -19.64 (Jun. 2023 ) + -84.473 (Sep. 2023 ) + -66.483 (Dec. 2023 ) = $-188.9 Mil.
OPKO Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -22.647 (Mar. 2023 ) + -0.365 (Jun. 2023 ) + 33.109 (Sep. 2023 ) + -38.294 (Dec. 2023 ) = $-28.2 Mil.
OPKO Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -7.717 (Mar. 2023 ) + -5.491 (Jun. 2023 ) + -3.572 (Sep. 2023 ) + -1.418 (Dec. 2023 ) = $-18.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health  (NAS:OPK) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, OPKO Health has a Sloan Ratio of -7.08%, indicating the company is in the safe zone and there is no funny business with accruals.


OPKO Health Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of OPKO Health's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health (OPKO Health) Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel director, officer: Chief Innovation Officer C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni director, officer: Vice Chairman and President 2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli director, other: Chairman of the Board OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen director, officer: SVP OPKO; Exec Chairman BRLI C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman director 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel director 1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez officer: CAO, Treasurer C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel director C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal officer: Exec.Dir .of Fin., CAO,Treas. OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137